EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.40
  • Today's Change0.55 / 19.30%
  • Shares traded587.37k
  • 1 Year change-72.97%
  • Beta1.0781
Data delayed at least 15 minutes, as of Mar 29 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eyepoint Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The Company has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The Company is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.

  • Revenue in USD (TTM)41.40m
  • Net income in USD-102.25m
  • Incorporated2008
  • Employees144.00
  • Location
    EyePoint Pharmaceuticals Inc480 Pleasant St Ste B300WATERTOWN 02472-2468United StatesUSA
  • Phone+1 (617) 926-5000
  • Fax+1 (617) 926-5050
  • Websitehttps://eyepointpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Paratek Pharmaceuticals Inc160.27m-63.57m111.67m268.00------0.6968-1.18-1.182.97-3.020.89941.672.88598,014.90-35.67-42.62-44.19-48.1685.61---39.66-124.083.22-2.662.99--23.1366.26-7.59---49.69--
Cidara Therapeutics Inc64.29m-29.80m112.15m73.00------1.74-0.458-0.4580.8619-0.04011.05--11.49880,657.60-48.49-70.43-101.14-120.17-----46.35-166.50--------29.69--29.83---17.35--
aTyr Pharma Inc10.39m-45.34m112.17m65.00--0.871--10.80-1.60-1.600.36552.420.0983--1.70159,784.60-42.91-45.75-47.28-53.23-----436.58-722.51----0.0175-------34.26--4.58--
Tiziana Life Sciences Ltd - ADR0.00-10.46m112.50m14.00--3,769.22-----0.1689-0.16890.000.00030.00----0.00-22.48---26.47--------------0.00------10.24------
Personalis Inc65.05m-113.32m113.10m395.00--0.5182--1.74-2.48-2.481.424.670.18887.283.71164,676.00-32.88-26.39-36.27-33.8320.5229.81-174.20-79.725.77--0.0118---23.9247.26-73.73--57.44--
Galera Therapeutics Inc0.00-62.22m114.78m31.00---------2.30-2.300.00-3.830.00----0.00-97.72-71.31-123.17-81.63-----------4.634.59------22.74---39.91--
Eyenovia Inc10.00m-18.90m115.59m43.00--5.59--11.56-0.5642-0.56420.31680.57220.3546--7.44232,558.10-67.04-82.88-153.31-124.23100.00---189.04-475.55---29.230.2623--600.00--35.36--95.35--
Eyepoint Pharmaceuticals Inc41.40m-102.25m116.63m144.00--1.20--2.82-2.74-2.741.112.830.18662.562.45287,527.80-46.09---53.05--79.89---246.97--4.92-74.330.2924--12.09---75.04------
VolitionRX Ltd306.39k-30.27m116.73m104.00------380.98-0.5478-0.54780.0055-0.04450.0134--7.202,946.06-133.66-102.95-270.09-139.00-----9,986.77-26,254.27---664.582.88--240.28---12.88--1.96--
Puma Biotechnology Inc228.03m2.00k118.94m192.00--5.4713.330.5216-0.0043-0.00435.100.46621.029.477.711,187,662.000.0009-24.020.0015-39.2675.8481.330.0009-22.631.672.200.8198---9.9252.46100.01---32.63--
Chromadex Corp72.05m-16.54m118.99m113.00--4.14--1.65-0.2405-0.24051.030.38451.292.0716.94637,610.60-29.56-54.44-43.29-80.4159.4058.35-22.96-46.661.78--0.0013--6.8227.7239.03---24.39--
Bioatla Inc0.00-106.48m119.49m66.00--0.6618-----2.74-2.740.003.790.00----0.00-44.35---48.71--------------0.00---100.00---11.61------
Mediwound Ltd26.50m-19.60m120.90m73.00--8.46--4.56-3.85-3.855.321.510.75968.434.77362,958.90-56.19-26.49-83.43-35.2049.6947.32-73.97-42.933.64-0.74670.0719--11.5060.39-44.63---12.39--
INmune Bio Inc374.00k-27.30m121.14m10.00--2.02--323.89-1.52-1.520.02093.350.0041--0.053637,400.00-30.04-38.64-32.80-40.98-----7,299.20-15,877.95---12.890.1965--106.63--10.02------
Data as of Mar 29 2023. Currency figures normalised to EyePoint Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

58.01%Per cent of shares held by top holders
HolderShares% Held
Franklin Advisers, Inc.as of 31 Dec 20225.73m16.81%
RA Capital Management LPas of 31 Dec 20223.37m9.89%
Suvretta Capital Management LLCas of 31 Dec 20223.35m9.82%
Adage Capital Management LPas of 31 Dec 20221.95m5.72%
BlackRock Fund Advisorsas of 31 Dec 20221.50m4.40%
The Vanguard Group, Inc.as of 31 Dec 20221.36m3.99%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2022742.58k2.18%
Millennium Management LLCas of 31 Dec 2022675.43k1.98%
Verition Fund Management LLCas of 31 Dec 2022555.53k1.63%
Citadel Advisors LLCas of 31 Dec 2022540.82k1.59%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.